The purpose of the study is to learn about the safety and effects of VERT-002 in treating these types of cancers. The study is divided into two parts. In the first part, researchers will determine the safest dose of VERT-002 and how well patients tolerate it. In the second part, they will further explore the drug’s effects and continue to monitor its safety. The study will help identify the best dose to use in future research.

Participants in the study will receive VERT-002 and will be closely monitored by healthcare professionals. The study will look at how the drug affects the cancer and any side effects that may occur. This research is important for developing new treatments for patients with advanced cancers that have limited options. The study is expected to continue for several years to gather comprehensive data on the drug’s effectiveness and safety.

The purpose of the study is to assess the safety and tolerability of mRNA-4359 when used alone and in combination with pembrolizumab. Participants will receive the treatment through injections, and the study will monitor how their bodies respond over time. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects. The study will also involve regular check-ups and tests to ensure the safety of the participants and to gather information on how the treatment affects the cancer.

The study will take place over several years, with participants being closely monitored by healthcare professionals. The goal is to better understand how mRNA-4359 can be used to treat advanced cancers and to determine the best way to use it in combination with existing treatments like pembrolizumab. This research could lead to new options for people with advanced solid tumors, providing hope for more effective treatments in the future.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

The main purpose is to see how many participants can go at least 12 weeks without their disease getting worse. After an initial screening, participants receive the infusion every few weeks and are checked regularly with scans and blood tests. Changes in tumor size are measured using standard criteria (RECIST) to determine if the cancer is shrinking, staying the same, or growing. Safety is monitored by asking about side effects and using questionnaires that assess quality of life throughout the study.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The purpose of this study is to determine if the combination of ceralasertib and durvalumab is more effective than docetaxel in treating patients with this type of lung cancer. Participants in the study will be randomly assigned to receive either the combination therapy or docetaxel. The study will monitor the overall survival of participants, which refers to the length of time patients live after starting the treatment. Other aspects being evaluated include how long the cancer stays under control, the quality of life reported by participants, and the safety and tolerability of the treatments.

The study will take place over a period of time, with participants receiving treatment for up to 24 months. During this time, participants will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for patients with advanced or metastatic non-small cell lung cancer.

The purpose of the study is to compare how the body absorbs and processes these two forms of pembrolizumab in patients who are receiving it as their first treatment for this type of lung cancer. Participants will receive either the subcutaneous or intravenous form of pembrolizumab, and the study will monitor how the drug behaves in the body over time. This includes looking at how much of the drug is present in the blood at different times and how long it stays in the body.

Throughout the study, researchers will also observe the overall health and quality of life of the participants, as well as any side effects they may experience. The study aims to provide valuable information on the safety and effectiveness of these two methods of administering pembrolizumab, which could help improve treatment options for patients with this type of lung cancer.

The purpose of the study is to find out if EP0031 is safe and how well it works in treating cancers with RET changes. The study is divided into different parts called modules. Module A will look at the safety of EP0031 and help determine the right dose to use. Modules B and C will test how well EP0031 works at shrinking tumors and will continue to monitor safety. The study will measure how tumors respond to treatment, how long the response lasts, and how long people live without their cancer getting worse. For some people in the study, tissue samples from their tumor may be taken before and during treatment to better understand how the medicine works.

During the study, people will take EP0031 regularly and visit the study site for check-ups. These visits will include physical examinations, blood tests, heart monitoring with an ECG, and scans to see how the cancer is responding to treatment. The study doctors will watch for any side effects and measure the amount of medicine in the blood to understand how the body processes it. Different groups of people will be placed into different cohorts based on their type of cancer, whether they have received previous RET-targeted treatment, and other factors. The study will continue until enough information is gathered about the safety and effectiveness of EP0031 in treating these types of cancer.

The study aims to determine whether the combination of divarasib and pembrolizumab works better than the standard treatment combination in treating this type of lung cancer. The medications will be given through different routes – divarasib as tablets taken by mouth, while pembrolizumab, pemetrexed, carboplatin, and cisplatin are given through an intravenous infusion (through a vein).

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life and symptoms related to their cancer, such as cough and breathing difficulties. The study will measure how long patients live without their cancer getting worse and their overall survival time.

The investigational medication being studied is Rinatabart Sesutecan (Rina‑S), which is given through an intravenous infusion, a process where the medicine is delivered directly into a vein using a small needle. The purpose of the study is to assess the anti‑tumor activity of this drug when used alone. The medication is administered in a series of treatment cycles, and participants are monitored regularly for any changes in tumor size, side effects, and overall health.

During the study, tumor measurements are evaluated using the RECIST criteria, a set of simple rules that help doctors decide whether the cancer is shrinking, staying the same, or growing. Participants have scheduled visits for blood tests, imaging scans, and safety checks, allowing researchers to observe how the drug works over time and to record any adverse events that may occur.

Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

The research is conducted in different stages to carefully monitor how the body reacts to these drug combinations. Initially, the focus is on determining the safest and most appropriate amount of medicine to give. Following this, the study expands to observe how well these combinations work in shrinking tumors. During the study, medical professionals will monitor various health indicators, such as vital signs and laboratory results, to ensure safety throughout the process.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

Patients in the study will receive ASP3082 for up to 8 weeks. During this time, doctors will check how the tumors respond to the treatment using imaging scans. The study will also involve taking samples from the tumor and blood at different times to understand how the treatment is working and why some tumors might stop responding to it. Patients with lung cancer must have already tried other standard treatments, including chemotherapy with platinum-based drugs and immunotherapy, and their cancer must have gotten worse. Patients with pancreatic cancer must have received one prior chemotherapy treatment that lasted at least 5 months before their disease progressed.

The study will measure several things to understand if the treatment is helpful. Doctors will look at whether tumors shrink or stop growing, how long any response lasts, and how long patients live without their cancer getting worse. They will also carefully track any side effects that occur during treatment. The study will examine changes in the body and in the tumor samples to learn more about how ASP3082 affects cancer cells and why some cancers might develop resistance to the treatment over time.

The purpose of the study is to find out if adding BMS-986504 to pembrolizumab and chemotherapy can help people with this type of lung cancer live longer without their cancer getting worse, and to see if it can help them live longer overall, compared to treatment with placebo plus pembrolizumab and chemotherapy. The study will also look at how well the cancer responds to treatment and how long any response lasts, as well as checking for any unwanted effects that the treatments may cause.

The study will be conducted in two phases. Participants will be randomly assigned to receive either BMS-986504 or placebo, both given together with pembrolizumab and chemotherapy. The specific chemotherapy medicines used will depend on the type of lung cancer each person has. Throughout the study, doctors will perform regular check-ups and scans to see how the cancer is responding to treatment and to monitor for any side effects. Treatment will continue for as long as it is helping and not causing unacceptable side effects.

The purpose of this study is to find out if taking osimertinib less often than the usual daily dose works just as well as taking it every day. Patients in this study will already have been taking osimertinib once daily for at least three months and will have shown a positive response to the treatment, meaning their cancer has gotten smaller or stayed stable. The study will compare how well the cancer stays under control when patients continue taking the medicine every day versus taking it less frequently.

During the study, patients will continue their treatment with osimertinib and will be monitored regularly to see how the cancer responds and to check for any side effects. The study will also look at how the treatment affects patients’ daily lives and overall well-being, as well as the costs associated with different dosing schedules. Patients will be asked to complete questionnaires about their symptoms and quality of life throughout the study period, which is expected to last up to two years for each participant.

The study also uses standard cancer treatments including chemotherapy drugs such as carboplatin, cisplatin, paclitaxel, and pemetrexed. Different combinations of these medications will be used depending on the specific type of lung cancer and previous treatments. The treatment involves receiving the modified immune cells through an intravenous infusion, along with the other medications.

The main purpose is to determine if this combination treatment is safe and to see how well patients tolerate it. The study will also look at whether the treatment helps control the cancer and how it affects quality of life. Patients will be monitored for side effects and will have regular scans to check how their cancer responds to the treatment. Blood tests will be done to measure how the immune system reacts to the treatment.

The main purpose of this research is to understand how the body processes nivolumab when it is given under the skin in two different doses, along with ipilimumab and chemotherapy. The study will look at how the medications work together and how they are processed by the body.

During the study, participants will receive nivolumab as an injection under the skin, while ipilimumab and chemotherapy medications will be given through a vein. The treatment will continue for up to 24 months. Throughout the study, doctors will monitor how participants respond to the treatment and check for any side effects that may occur.

The study consists of two parts. The first part tests the safety of combining the medications and determines the right dose. The second part compares how well the combination of medications works versus using just pembrolizumab by itself. The study includes patients whose cancer cells have high levels of a protein called PD-L1 and who have not received previous treatment for their advanced cancer.

During the study, participants will be randomly assigned to receive either the combination of both medications or pembrolizumab alone. The medications will be given in repeated cycles, with regular check-ups to monitor the patient’s health and how well the treatment is working. Doctors will use various medical tests and imaging scans to track the progress of the cancer throughout the treatment period.

The main purpose of this study is to determine how well zelenectide pevedotin works in treating patients whose tumors have this specific NECTIN4 amplification. The medication is a type of drug called a bicyclic peptide, which is designed to target specific cancer cells. The study will include patients with two different types of non-small cell lung cancer: squamous and non-squamous forms of the disease.

During the study, participants will receive zelenectide pevedotin through intravenous infusion. The treatment will be given in cycles, with regular medical check-ups to monitor the patient’s health and how well the treatment is working. The maximum dose that can be given is 6 milligrams per square meter of body surface area. The study team will track if the tumors shrink, stay the same size, or grow during the treatment period.

The purpose of this research is to determine if patients can benefit from a shorter duration of standard treatment while maintaining its effectiveness. The study involves patients who have been receiving treatment for about 6 months and whose cancer has not gotten worse during this time. These patients will continue receiving their current treatment for up to 18 months while being monitored for any changes in their condition.

During the study, doctors will regularly check how the cancer responds to treatment through various medical examinations. The medications will be given at specific doses – pembrolizumab at up to 200 mg per dose and pemetrexed at 500 mg per square meter of body surface area. The treatment will continue for up to 18 months, during which time patients will be monitored for any changes in their health and how well the treatment is working.

The treatment being tested includes a combination of Adagrasib, Pembrolizumab, and chemotherapy drugs such as Cisplatin, Pemetrexed, and Carboplatin. Pembrolizumab is a type of medication that helps the immune system fight cancer, while chemotherapy uses drugs to kill cancer cells. The study will compare this combination to a similar treatment that includes a placebo instead of Adagrasib. Another medication, Palonosetron, is used to help manage side effects like nausea during the treatment.

Participants in the study will receive these treatments through infusions, which means the medication is given directly into the bloodstream. The study will last for a period of time, and researchers will monitor the participants to see how well the cancer responds to the treatment and how long the patients live. The aim is to determine if the addition of Adagrasib can improve outcomes for patients with this specific type of lung cancer.

The purpose of this study is to see how well M9140 works in treating people with advanced NSCLC. Participants in the study will receive M9140 through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in two parts, and participants will be monitored to see how their cancer responds to the treatment. Researchers will also keep track of any side effects that occur during the study.

Throughout the study, doctors will use a set of guidelines called RECIST to measure how the cancer is responding to the treatment. They will look at things like whether the cancer has shrunk, stayed the same, or grown. The study will also gather information on how long any positive effects last and how long it takes for the treatment to start working. Additionally, researchers will check the levels of M9140 in the blood and see if the body produces any antibodies against the drug. The study is expected to continue until early 2028.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of this study is to evaluate the safety and effectiveness of the combination of ABBV-400 and Budigalimab in patients with advanced or metastatic non-squamous NSCLC. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor participants for any side effects and changes in their cancer to determine the best dose for future studies.

Throughout the study, participants will be closely observed to assess how their cancer responds to the treatment. The study aims to find out if this combination can help control the disease and improve the quality of life for patients with this type of lung cancer. The trial will continue until the researchers gather enough information to understand the treatment’s impact on the disease.

The purpose of this research is to determine if these medications can work together safely and effectively to treat advanced lung cancer. Roginolisib is given as a tablet that patients take by mouth, while dostarlimab and docetaxel are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

During the study, participants will receive different combinations of these medications. Some patients will receive roginolisib with dostarlimab, while others will receive all three medications together. The study will monitor how patients respond to the treatment and track any side effects that may occur. Regular medical check-ups and blood tests will be performed to ensure patient safety throughout the treatment period.

The purpose of the study is to determine if the combination of Acasunlimab and Pembrolizumab is more effective than Docetaxel in treating patients with NSCLC. Participants in the study will receive either the combination of Acasunlimab and Pembrolizumab or Docetaxel. The study will monitor the overall survival of participants, which means how long they live after starting the treatment. It will also look at other factors like how long the cancer does not get worse, the response of the cancer to the treatment, and any side effects experienced by the participants.

The study will take place over several years, and participants will be closely monitored throughout the process. The trial aims to provide valuable information on whether the new combination of treatments can offer better outcomes for patients with NSCLC compared to the current standard treatment. This research is important for developing more effective therapies for lung cancer patients in the future.

The purpose of this study is to compare the effectiveness of the combination of efti, pembrolizumab, and chemotherapy against the standard treatments currently used for this type of lung cancer. Participants in the study will receive either the new combination of treatments or the standard treatments. Some participants may receive a placebo, which looks like the treatment but does not contain any active medication. The study will be conducted over a period of time, and participants will be monitored regularly to assess their response to the treatment and any side effects they may experience.

Throughout the study, participants will undergo various assessments to track their health and the progress of their cancer. These assessments will help researchers understand how well the new treatment combination works compared to the standard treatments. The study aims to provide valuable information that could lead to improved treatment options for patients with advanced/metastatic non-small cell lung cancer.

The purpose of the study is to compare the effects of these two treatment combinations. Participants will be randomly assigned to one of the two groups. The study will involve regular visits to the clinic for treatment and monitoring. Treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will continue for a period of time, during which participants will receive their assigned treatments and undergo various assessments to monitor their health and the progress of the cancer.

Throughout the study, participants will be closely monitored by healthcare professionals. The study aims to determine which treatment combination is more effective in managing the cancer and improving the overall survival of patients. Participants will also be monitored for any side effects or changes in their condition. The information gathered from this study will help in understanding the best treatment options for patients with Metastatic Non-Small Cell Lung Cancer.

Participants in the study will receive the combination of Amivantamab and Cetrelimab. The study will be conducted in two phases. In the first phase, researchers will determine the most suitable dose of the combination treatment. In the second phase, they will evaluate how effective the treatment is in reducing the size of the cancer or stopping its growth. The study will also look at the safety of the treatment and any side effects that may occur.

This trial is designed to help understand how the combination of these two treatments can benefit people with NSCLC, especially those whose cancer has specific characteristics related to EGFR and PD-L1 status. The study aims to provide valuable information that could lead to better treatment options for patients with this type of lung cancer.

The purpose of this study is to see how effective the combination of these two drugs is in treating patients whose cancer has progressed after initial treatment with Osimertinib alone. Patients participating in the study will take these medications in the form of film-coated tablets, which are taken orally. The study will monitor how the cancer responds to the treatment over time, and researchers will collect data on the overall response rate, which means how well the cancer shrinks or disappears after treatment.

Participants will be closely observed throughout the study to ensure their safety and to gather information on any side effects they might experience. The study aims to provide valuable insights into whether adding Savolitinib to Osimertinib can offer a new treatment option for patients with this specific type of lung cancer. The trial is expected to continue until 2025, allowing researchers to gather comprehensive data on the effectiveness and safety of this treatment combination.

The purpose of the study is to compare the effects of the combination of CC-486 and pembrolizumab against pembrolizumab with a placebo in patients with NSCLC. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab with a placebo. The study will monitor the participants over a period to assess how well the treatments work and to check for any side effects. The trial will help researchers understand if the combination of CC-486 and pembrolizumab can improve outcomes for patients with this type of lung cancer.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study is expected to continue until 2025, providing valuable information on the potential benefits and risks of using CC-486 in combination with pembrolizumab for treating advanced NSCLC. This research could lead to new treatment options for patients with this challenging form of lung cancer.

The purpose of the study is to evaluate the effectiveness of each treatment by looking at how well the cancer responds. Participants in the study will receive one or more of these medications, which may be given as tablets, infusions, or capsules, depending on the specific treatment. Some participants may receive a placebo. The study will monitor the participants over a period of time to observe the effects of the treatments on their cancer.

Throughout the study, participants will undergo regular assessments to track the progress of their cancer and any changes in their health. The study aims to gather information on how these treatments can help manage NSCLC, especially in cases where the cancer has not responded to previous therapies. This research is important for developing new treatment options for patients with this type of lung cancer.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of time, with regular monitoring to assess the effects of the treatments. The study will also include a placebo group to help understand the effectiveness of the treatments being tested.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the effectiveness and safety of these treatment combinations for patients with Metastatic Squamous Non-small Cell Lung Cancer. This research could potentially lead to improved treatment options for this type of cancer in the future.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from getting worse, which is known as progression-free survival. Participants in the study will be randomly assigned to receive either divarasib, sotorasib, adagrasib, or a placebo. The study will monitor the participants over a period of time to see how the treatments affect their cancer and overall health. This includes looking at how long the treatments can keep the cancer from progressing and any side effects that may occur.

Throughout the study, participants will have regular check-ups and tests to assess their health and the status of their cancer. The study aims to provide valuable information on the best treatment options for patients with KRAS G12C-positive advanced or metastatic non-small cell lung cancer, potentially leading to improved outcomes for those affected by this condition.

Participants in the study will receive either Lazertinib or Gefitinib. The study will monitor how long the cancer does not worsen, which is known as progression-free survival. The trial will also look at other factors such as the overall response to the treatment, how long any response lasts, and the overall survival of the participants. Additionally, the study will measure the levels of Lazertinib in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. Participants’ quality of life will also be assessed using questionnaires designed to evaluate the impact of the treatment on their daily lives.

This study is important for understanding which treatment might be more effective for patients with NSCLC that have specific mutations in the epidermal growth factor receptor (EGFR), which is a protein that can affect the growth of cancer cells. The trial aims to provide valuable information that could help improve treatment options for patients with this type of lung cancer.

The purpose of the study is to demonstrate that FYB206 is as effective as Keytruda when used alongside chemotherapy. Participants in the study will receive either FYB206 or Keytruda through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which the participants’ health will be closely monitored. This includes checking how well the cancer responds to the treatment, whether it shrinks or disappears, and observing any side effects or changes in health indicators like vital signs and laboratory test results.

Throughout the study, researchers will also assess the participants’ immune response to the treatments by measuring the presence of antibodies. Antibodies are proteins that the body produces to fight off foreign substances, and sometimes they can form against medications. The study will also track the levels of the drug in the participants’ blood at various times to ensure the treatment is being administered effectively. The trial is expected to continue until the end of 2027.

The study is divided into three parts. In the first part, researchers will focus on understanding how safe and tolerable STX-241 is for patients, as well as determining the right dose to use in the next phase. The second part will continue to assess safety and will aim to find the best dose to recommend for further testing. The third part will look at how effective STX-241 is at treating the cancer when given at the recommended dose. Throughout the study, participants will take the medication orally and will be monitored for any side effects or changes in their condition.

Participants in the trial will have their health closely monitored, including regular check-ups and tests to track their response to the treatment. The study aims to provide valuable information on the potential benefits and risks of using STX-241 for treating advanced NSCLC, which could lead to new treatment options for patients with this challenging condition.